Literature DB >> 24435928

ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.

Lin Wang1, Yanjiang Li, Xiaoqing Yang, Huiqing Yuan, Xiangzhi Li, Mei Qi, Yannicca W Y Chang, Chunni Wang, Weiwei Fu, Muyi Yang, Juan Zhang, Bo Han.   

Abstract

BACKGROUND: Approximately 50% of prostate cancer (PCa) patients in Western countries harbor ERG rearrangement with concurrent ERG overexpression. Overexpression of SOX4 has been shown to play important roles in multiple cancers including PCa. However, the link between these two critical genetic aberrations was unclear.
METHODS: Fluorescence in situ hybridization and immunohistochemistry were utilized to detect ERG rearrangement and SOX4 expression. Cellular function was evaluated by transwell, wound healing assays, and cell adhesion assay, respectively. Interaction between ERG and SOX4 was arrayed by co-immunoprecipitation, Real-time PCR, Western blot, and siRNA. Direct binding of ERG to the promoter of SOX4, as well as epigenetic modifications of their promoters after TGF-β1 treatment was monitored by chromatin immunoprecipitation.
RESULTS: ERG regulated SOX4 expression via binding to its promoter. Silencing both of them showed duplicate effects on restoring the epithelial characteristics, increasing cellular adhesion and decreasing capacity of cellular migration and invasion. ERG and SOX4 have cooperative roles in TGF-β1-induced epithelial to mesenchymal transition (EMT) process. In addition, TGF-β1 stimulation increased levels of chromatin marks associated with active genes (H3K4me3, H416ac), and decreased levels of repressive marks (H3K27me3) at their promoters. 5-aza and TSA treatment changed expressions of ERG and SOX4. Clinically, overexpression of SOX4 is associated with ERG rearrangement status in PCa and ERG+/SOX4+ defined a subset of PCa patients with poor prognosis.
CONCLUSION: Our findings define a key role for ERG/SOX4 in the development of a subset of PCa and highlight the clinical importance of identifying molecularly defined tumor subgroups.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  EMT; ERG; SOX4; TGF-β1; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24435928     DOI: 10.1002/pros.22783

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  28 in total

1.  Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.

Authors:  Jake Higgins; Michele Brogley; Nallasivam Palanisamy; Rohit Mehra; Michael M Ittmann; Jun Z Li; Scott A Tomlins; Diane M Robins
Journal:  Horm Cancer       Date:  2015-01-29       Impact factor: 3.869

Review 2.  SOX4: The unappreciated oncogene.

Authors:  Carlos S Moreno
Journal:  Semin Cancer Biol       Date:  2019-08-21       Impact factor: 15.707

3.  SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo.

Authors:  Chi-Neu Tsai; Shu-Chuan Yu; Chao-Wei Lee; Jong-Hwei Su Pang; Chun-Hsin Wu; Sey-En Lin; Yi-Hsiu Chung; Chia-Lung Tsai; Sen-Yung Hsieh; Ming-Chin Yu
Journal:  Oncogene       Date:  2020-05-13       Impact factor: 9.867

4.  Oldhamianoside II inhibits prostate cancer progression via regulation of EMT and the Wnt/β-catenin signaling pathway.

Authors:  Kaizhi Li; Xuemei Zhan; Jingyong Sun; Tianfeng Wang; Hongyan Dong; Fanbo Jing; Dongmei Li; Yu Cao; Yali Liu; Lin Wang; Shengnan Li
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

5.  SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients.

Authors:  Guo-Dong Song; Yu Sun; Hong Shen; Wei Li
Journal:  Tumour Biol       Date:  2015-01-16

6.  Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.

Authors:  Mei Qi; Zhiyan Liu; Chengwu Shen; Lin Wang; Jiping Zeng; Chunni Wang; Congcong Li; Weiwei Fu; Yi Sun; Bo Han
Journal:  Tumour Biol       Date:  2014-12-28

Review 7.  SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis.

Authors:  J Chen; H L Ju; X Y Yuan; T J Wang; B Q Lai
Journal:  Clin Transl Oncol       Date:  2015-08-07       Impact factor: 3.405

Review 8.  MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4.

Authors:  Yang Li; Peirui Chen; Lingling Zu; Bin Liu; Min Wang; Qinghua Zhou
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

9.  CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2.

Authors:  M Qi; M Jiao; X Li; J Hu; L Wang; Y Zou; M Zhao; R Zhang; H Liu; J Mi; L Zhang; L Liu; Y Gong; B Han
Journal:  Oncogene       Date:  2017-11-06       Impact factor: 9.867

10.  miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4.

Authors:  Yang Li; Lingling Zu; Yuli Wang; Min Wang; Peirui Chen; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.